News
(April 9, 2015) Innovative Research's Rabbit Anti Mouse Fibrinogen IgG Fraction was recently used in the following study:
Host protein C inhibitor inhibits tumor growth, but promotes tumor metastasis, which is closely correlated with hypercoagulability
N Akita, N Ma, T Okamoto, K Asanuma, K Yoshida - Thrombosis Research, 2015
...CA, USA). Rabbit antimouse fibrinogen IgG and Alexa Fluor 594 labeled goat antirabbit IgG were purchased from Innovative Research, Inc. (Novi, MI, USA), and Molecular Probes (Eugene, OR, USA), respectively.
While funding and grants for young researchers has become increasingly harder to find there is new hope in looking at alternative sources for funding.
Outside of NIH, many organizations offer grants specific to their causes and designed especially for young researchers who are working toward a common goal
.As the effects of Toxoplasma Gondii on human behavior are hotly debated extensive studies have been examining its effects on infected mice. These studies may have found a biological explanation for changes in their behavior.
Findings suggest that affected mice lose their ingrained fear of cats. This allows them to be eaten and gives the parasite a chance to successfully sexually reproduce. It is known that this can only occur in the intestines of members of the cat family.
Pharmacokinetics and Pharmacodynamics of Tissue Plasminogen Activator Administered Through an External Ventricular Drain
AH Kramer, C Jenne, JK Holodinsky, S Todd - Neurocritical Care, 2015Enzyme lined immunosorbent assay (ELISA) testing was used to measure TPA (Innovative Research, Novi, MI) and D-dimer concentrations. D-dimer is a fibrin Neurocrit Care 123 Page 3.
According to FierceBiotech's March 18 article, GlaxoSmithKline (GSK) is testing out an Ebola vaccine in Africa. It is interested to find out if an immune reaction strong enough to overcome Ebola will occur.
If no strong immune response occurs, GSK will test Emergent BioSolutions' Ebola shot as a booster to their own vaccination. The two companies have partnered in this endeavor in Phase I trials at the University of Oxford.